What is PEG-MGF?
PEG-MGF is a synthetic piece of mechano growth factor, an IGF-1 splice variant that loaded muscle makes, with polyethylene glycol attached to make it last longer. The muscle-growth claim comes from cell studies that a two-company replication could not reproduce, and no published study has tested PEG-MGF itself in cells, animals or people.
Video overview · 3:22
PEG-MGF (Mechano Growth Factor): Does It Build Muscle? What the Research Shows
Where mechano growth factor comes from, the cell studies behind the muscle claim, the two-company replication that found no effect, why PEG-MGF itself has never been studied, and its FDA, compounding and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
PEG-MGF is sold online as a muscle-building peptide, and the FDA's compounding panel is due to review it by early 2027. The story behind it starts with a real discovery in stretched muscle. But PEG-MGF itself has never been studied. Here's what's actually known.
In 1996, a London team led by Geoffrey Goldspink found an unusual version of the growth factor IGF-1 in stretched muscle. It was later named mechano growth factor. What's sold online is a short lab-made piece of its tail, about twenty-four amino acids. PEG-MGF is that piece with polyethylene glycol attached, meant to make it last longer.
Here's the idea. Loading a muscle switches on mechano growth factor, which was proposed to wake up muscle stem cells, called satellite cells, so they multiply and help repair. In older rats, muscle made much less of it. Whether a vial of the lab-made piece does any of this in a person has never been tested.
In 2002, the original team reported that the tail piece made muscle cells multiply in a dish. A 2011 study saw longer growth in muscle cells from young donors, but not from older ones. Then, in 2014, scientists at two drug companies tried to repeat the work. The peptide had no effect on mouse or human muscle cells, while ordinary IGF-1 worked in the same tests.
Outside muscle, modified versions of the peptide helped heart function after heart attacks in mice, and helped bone and cartilage repair in rabbits. But those studies used other forms of the peptide, some stabilized differently or released from a scaffold. We found no published study of PEG-MGF itself, in cells, animals or people.
In people, nobody has been given MGF or PEG-MGF in a published or registered trial. The one well-known human study only measured the body's own MGF: after heavy leg exercise, it rose in eight young men, but not in seven older men.
PEG-MGF is not FDA approved. The FDA warns it may carry a significant risk of immune reactions, notes impurity concerns, and says it has found no human exposure data. It's on the agenda for the FDA's next compounding advisory meeting. Anti-doping labs have found mislabeled MGF products, and the World Anti-Doping Agency bans mechano growth factors at all times.
Does PEG-MGF build muscle in people? Unproven: no human trial has given it. Does MGF activate muscle stem cells? Mixed: the original lab says yes, a two-company replication found nothing. Does PEG-MGF work like MGF, only longer? Unknown: it has never been studied. And is it allowed in sport? No.
The bottom line: mechano growth factor is a real form of IGF-1 that muscle makes when it's loaded. But the muscle-building claim rests on cell studies that a careful replication couldn't confirm, PEG-MGF has never been studied, and it isn't approved. For every study and source, see the PEG-MGF profile on PepsRadar dot com.
Biological role or research focus
Growth-factor-related research.
Endogenous MGF, experimental MGF fragments, and PEG-MGF seller preparations must be distinguished.
Role reference: Mechano-growth factor peptide has no apparent effect on myoblasts or muscle stem cells · Am J Physiol Endocrinol Metab 2014 ↗
Names you may encounter
PEG MGF · pegylated mechano growth factor
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Pegylated growth-factor-related research material
- Main research area
- Muscle-cell signaling claims
- Evidence featured
- Related-compound cell study
- Source check
- October 4, 2026
Quick answers
- Is PEG-MGF FDA approved?
- No. No FDA-approved drug contains PEG-MGF. Source ↗
- Is PEG-MGF safe?
- Unapproved pegylated MGF. FDA found no human exposure data and flagged immune-reaction and impurity risks; its safety in people is unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is PEG-MGF banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S2.3 Growth factors and growth factor modulators). Source ↗
- Has the FDA taken action over PEG-MGF?
- Yes. Our records list 2 FDA actions naming it, most recently on April 15, 2026: FDA listed Mechano growth factor, pegylated (PEG-MGF) among five bulk substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027 (date not yet set). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| MGF replication experiment (2013) | Human and mouse muscle-cell systems and primary muscle stem cells. | |
| MGF E peptide · muscle cells (2002) | Cell study | Cultured muscle precursor cells (myoblasts). |
| Natural MGF after exercise · young vs older men (2003) | Human observational study | 8 young men (25–36) and 7 older men (70–82). |
| Stabilized E-domain peptide · heart attack in mice (2013) | Animal study | Mice with an induced heart attack. |
Claim check
False What is metatrutide ('GLP-4')? What's actually in the vial
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Related-compound cell study · 2013
MGF replication experiment
Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells.
- Population / model
- Human and mouse muscle-cell systems and primary muscle stem cells.
- Study design
- Attempts to reproduce published claims using MGF fragments; IGF-1 served as a positive comparator.
- Main finding
- The tested MGF peptides did not increase proliferation or inhibit differentiation as claimed. IGF-1 produced responses in the comparison experiments.
- Limits & context
- This is not a clinical trial of PEG-MGF. Endogenous IGF-1 splice variants, isolated fragments, and pegylated seller preparations are different materials.
Cell study · 2002
MGF E peptide · muscle cells
Does the MGF E peptide act differently from mature IGF-1 in muscle cells?
- Population / model
- Cultured muscle precursor cells (myoblasts).
- Study design
- Comparison of the synthetic E peptide with mature IGF-1, with the IGF-1 receptor blocked in some experiments.
- Main finding
- The original laboratory reported that the E peptide increased myoblast proliferation and held back differentiation, even with the IGF-1 receptor blocked.
- Limits & context
- A 2014 two-company replication did not reproduce these effects. Cell findings do not show muscle growth in people, and this was not PEG-MGF.
Human observational study · 2003
Natural MGF after exercise · young vs older men
Does exercise switch on the body's own MGF?
- Population / model
- 8 young men (25–36) and 7 older men (70–82).
- Study design
- Muscle biopsies 2.5 hours after a heavy knee-extension session; nobody was given MGF.
- Main finding
- MGF messenger RNA rose significantly in the young men but not in the older men.
- Limits & context
- Measures the body's own gene activity, not the effect of taking a synthetic peptide. Small groups.
Animal study · 2013
Stabilized E-domain peptide · heart attack in mice
Could a stabilized MGF E-domain peptide protect the heart?
- Population / model
- Mice with an induced heart attack.
- Study design
- A chemically stabilized E-domain peptide given at the time of injury, with heart function measured two weeks later.
- Main finding
- Treated mice kept more heart contractility and showed less cell death.
- Limits & context
- The peptide was stabilized by amidation and D-amino acids, not polyethylene glycol, so it is not PEG-MGF. Mouse heart results are not human data.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming PEG-MGF as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 1 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. ↗
Frontiers in endocrinology · 2026 · Journal Article, Review
Read available full text ↗
Risks & interactions
Unapproved pegylated MGF. FDA found no human exposure data and flagged immune-reaction and impurity risks; its safety in people is unknown.
No published human safety studies were found, and FDA says it identified no human exposure data. Lab work on non-pegylated MGF fragments found no clear muscle-cell effect and does not address PEG-MGF safety.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- Possible immune reactions (immunogenicity) and peptide impurities, per FDA's compounding safety listing
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks ↗ · MGF peptide has no apparent effect on myoblasts or muscle stem cells (2014) ↗
Safety evidence & remaining uncertainty
FDA reports no identified human-exposure data. An assumed longer persistence from pegylation is not a substitute for measured pharmacokinetics or safety.
Source: FDA · Peptide compounding safety concerns ↗
What FDA flagged
FDA warns PEG-MGF may carry a significant risk of immune reactions, notes impurity and characterization concerns, and says it has not identified any human exposure data. Anti-doping laboratories have found mislabeled and modified MGF products in illicit channels.
Source: FDA · Bulk substances that may present significant safety risks ↗
FDA compounding review
FDA has listed pegylated mechano growth factor (PEG-MGF) among five substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027. No date had been set when this was checked. A committee vote is advice to FDA, and inclusion on the bulks list would not make it an approved drug.
Source: FDA · Pharmacy Compounding Advisory Committee meeting before the end of February 2027 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "Mechano growth factor pegylated (PEG-MGF)". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S2.3 Growth factors and growth factor modulators
S2.3 names "Mechano growth factors (MGFs)"; the pegylated form is likely covered. source
FDA actions
- FDA listed Mechano growth factor, pegylated (PEG-MGF) among five bulk substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027 (date not yet set). Any committee vote is advisory. (2026-04-15) source
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing PEG-MGF among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
No registered or published trial has given MGF or PEG-MGF to people. The best-known human study only measured the body's own MGF: after heavy leg exercise it rose in young men but not in older men. Mechano growth factors are prohibited at all times under the 2026 WADA list (S2.3).
Source: WADA 2026 Prohibited List ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
Mechano growth factor (IGF-1Ec in people, IGF-1Eb in rodents) was described in 1996 in stretched muscle. Its original researchers proposed that its tail piece, the E peptide, activates muscle stem (satellite) cells and keeps them multiplying, through a receptor different from the IGF-1 receptor.
The products sold online are a synthetic E-peptide of about 24 amino acids, often chemically modified; PEG-MGF adds polyethylene glycol. Studies on heart, bone and cartilage used peptides stabilized in other ways or released from scaffolds, not PEG-MGF.
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- Endogenous MGF, experimental MGF fragments, and PEG-MGF seller preparations must be distinguished.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is the linked paper a PEG-MGF clinical trial?
No. It concerns related MGF fragments in cell systems.
Why do product names need special scrutiny here?
The term MGF has been applied to different sequences and biological entities. Exact material identity determines whether a paper is relevant.
Has PEG-MGF itself been studied?
No peer-reviewed study of PEG-MGF itself was found, in cells, animals or people. Claims about it extrapolate from studies of other MGF peptides.
Source: Review of performance-enhancing GH and IGF-1 peptides · Front Endocrinol 2026 ↗
Is MGF allowed in sport?
No. Mechano growth factors are named in the 2026 WADA Prohibited List under S2.3 and are prohibited at all times.
Source: WADA 2026 Prohibited List ↗
References & editorial record
- FDA · Compounding safety concerns ↗
- PubMed · Related compound, laboratory study · PMID 24253050 ↗
- WADA 2026 Prohibited List ↗
- Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. ↗
- Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. ↗
- The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction. ↗
- Full-length MGF in doping controls · Growth Horm IGF Res 2014 ↗
- FDA · Pharmacy Compounding Advisory Committee meeting before the end of February 2027 ↗
- Review of performance-enhancing GH and IGF-1 peptides · Front Endocrinol 2026 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
